LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Denali Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

18.11 -8.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

18.03

Max

19.01

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.6M

-129M

EPS

-0.73

Angestellte

503

EBITDA

8.9M

-125M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+93.17% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

87M

3.3B

Vorheriger Eröffnungskurs

26.51

Vorheriger Schlusskurs

18.11

Nachrichtenstimmung

By Acuity

50%

50%

158 / 349 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Denali Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. März 2026, 17:33 UTC

Wichtige Nachrichtenereignisse

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27. März 2026, 17:00 UTC

Wichtige Nachrichtenereignisse

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27. März 2026, 16:03 UTC

Wichtige Nachrichtenereignisse

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27. März 2026, 14:50 UTC

Wichtige Markttreiber

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27. März 2026, 14:37 UTC

Akquisitionen, Fusionen, Übernahmen

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27. März 2026, 14:29 UTC

Wichtige Nachrichtenereignisse

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27. März 2026, 14:16 UTC

Wichtige Nachrichtenereignisse

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27. März 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. März 2026, 19:16 UTC

Market Talk
Wichtige Nachrichtenereignisse

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27. März 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27. März 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27. März 2026, 19:03 UTC

Market Talk
Wichtige Nachrichtenereignisse

Global Forex and Fixed Income Roundup: Market Talk

27. März 2026, 19:02 UTC

Market Talk
Wichtige Nachrichtenereignisse

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27. März 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27. März 2026, 17:36 UTC

Wichtige Nachrichtenereignisse

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27. März 2026, 17:34 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27. März 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27. März 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27. März 2026, 16:32 UTC

Market Talk
Wichtige Nachrichtenereignisse

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27. März 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. März 2026, 15:43 UTC

Market Talk
Wichtige Nachrichtenereignisse

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27. März 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. März 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27. März 2026, 15:00 UTC

Wichtige Nachrichtenereignisse

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27. März 2026, 15:00 UTC

Wichtige Nachrichtenereignisse

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27. März 2026, 15:00 UTC

Wichtige Nachrichtenereignisse

Fed's Barkin Says Iran War Raising Economic Uncertainty

27. März 2026, 14:36 UTC

Market Talk
Wichtige Nachrichtenereignisse

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27. März 2026, 14:26 UTC

Market Talk
Wichtige Nachrichtenereignisse

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27. März 2026, 14:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. März 2026, 14:14 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Denali Therapeutics Inc Prognose

Kursziel

By TipRanks

93.17% Vorteil

12-Monats-Prognose

Durchschnitt 35.08 USD  93.17%

Hoch 42 USD

Tief 25 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Denali Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

15 ratings

14

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

13.355 / 16.44Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

158 / 349 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat